A Value Creation Event to Unveil a Pivotal Corporate Milestone is a Don’t Miss Situation

December 19, 2024

DENVER, Colo., Dec 19, 2024 (247marketnews.com)- Siyata Mobile (NASDAQ: SYTA), Trio Petroleum (NYSE: TPET), Bio-Path (NASDAQ: BPTH), Phio Pharmaceuticals (NASDAQ: PHIO), Glimpse Group (NASDAQ: VRAR), and Painreform (NASDAQ: PRFX)

Sit back, ignore the noise, and prepare for a wealth creation event.

Siyata Mobile (NASDAQ: SYTA) just set its Press Conference for January 9, to cover an “Value Creation Event” to unveil a “Pivotal Corporate Milestone” and considering Siyata’s recent accomplishments, the event must be something special.

“Siyata is entering a transformative phase, and this development marks the culmination of months of strategic negotiations and execution. All shareholders are strongly encouraged to attend to appreciate the significant implications for 2025.” Marc Seelenfreund, Siyata’s CEO

Some of Siyata’s recent events that weren’t big enough to warrant a press conference include * Record revenue growth, as SYTA more than tripled its year-over-year third quarter revenue * Achieving stocked status at top carriers, including AT&T (NYSE: T) and T-Mobile (NASDAQ: TMUS), a key business milestone that’s typically reserved for device leaders like Apple (NASDAQ: AAPL), Samsung, LG, and Sony (NYSE: SONY) * Rolling out new cutting-edge technology * Larger order for Q1 2025 * Recent order from a prominent national Dutch transportation company to springboard Siyata’s international expansion* and many others.

Siyata is reporting4.1 million outstanding shares, so it’s already extremely undervalued, just based on its recent accomplishments and financial results, and the unveiling should only increase the value proposition.

“Siyata is in the best position it’s been in since our company’s inception, as our capital expenditures have directly improved all performance metrics, and we look forward to delivering continued successful results. Please tune into our upcoming press conference, which will highlight a next level shareholder value creation event that you surely won’t want to miss.” Seelenfreund

Trio Petroleum (NYSE: TPET) reported entering into a non-binding Letter of Intent to acquire 100% working interest in certain petroleum and natural gas properties held by Novacor Exploration, in the Lloydminster, Saskatchewan heavy oil region.

Trio believes that, if it consummates the mostly shares acquisition, it could strategically position itself to expand its operations into one of North America’s most promising heavy oil basins, with upside potential for long term production and reserve growth, in a heavy oil area that offers efficient development and low operational costs.

Current production is approximately 70 barrels per day with potential for 4 additional re-entry wells and two fully equipped locations to be reactivated each capable of an additional 70 barrels in total per day, as well as other wells that can be reactivated for additional production.

An August 2024 Reserve Report stated that 91.5MBBL total proved and probable oil for those wells currently being produced.

Robin Ross, Trio’s Chief Executive Officer, stated, “We are excited to acquire an initial footprint in this very lucrative oil and gas area of Canada and home to some of the largest players in the industry such as Cenovus Energy, Canadian Natural Resources, Baytex Energy, Rife Resources and many others who have made Heavy Oil a staple of their operation, and where numerous opportunities to acquire additional highly economic fields exist.

“Trio’s relationship with Novacor is very important, because Novacor has a long history of oil and gas development in the area. Trio’s plan is to aggressively grow its footprint in the area utilizing Novacor as an operator of the assets. The initial project has the capability to rapidly double production, and we are looking forward to a long and prosperous relationship with Novacor. Our focus remains on acquiring projects that generate immediate cash flow or offer transformative growth potential with strategic investment like the Asphalt ridge Project in Utah. We believe that this approach aligns with our long-term vision of creating exponential value while managing risk and resources effectively.”

Bio-Path (NASDAQ: BPTH) reported that preclinical studies of BP1001-A, which downregulates growth factor receptor-bound protein 2 (Grb2) expression to increase insulin sensitivity and helps lower blood glucose level in Type 2 diabetes patients, confirmed BP1001-A as a potential treatment for obesity and related metabolic diseases in Type 2 diabetes patients.

Peter H. Nielsen, Bio-Path’s President and Chief Executive Officer, stated, “The success of our initial preclinical testing, which supports the mechanism of action and highlights the efficacy of BP1001-A to enhance insulin sensitivity, further validates BP1001-A as a potential treatment for obesity in Type 2 diabetes patients. The failure of leading weight loss medications to induce weight loss in obese patients who have Type 2 diabetes creates a compelling need for an alternative method of lowering blood glucose in obese patients who have Type 2 diabetes.

“We are excited by the rapid progress we have made advancing BP1001-A as a potential treatment for obesity and related metabolic diseases in Type 2 diabetes patients based on previous BP1001-A preclinical studies as they support our continued and rapid development of this promising program.”

Phio Pharmaceuticals (NASDAQ: PHIO) reported that the Safety Monitoring Committee (SMC) recommended dose escalation in Phio’s Phase 1b clinical trial to assess PH-762’s safety and tolerability in the treatment of Stages 1, 2, and 4 cutaneous squamous cell carcinoma, Stage 4 melanoma and Stage 4 Merkel cell carcinoma, following PH-762’s encouraging safety profile in second cohort.

“Safety and efficacy data from our clinical trial continues to be encouraging as we develop PH-762 for the treatment of cutaneous carcinomas. We look forward to continued enrollment in the clinical study,” stated Mary Spellman MD, Phio’s acting Chief Medical Officer.

The Glimpse Group (NASDAQ: VRAR) reported that its subsidiary, Brightline Interactive, entered into an initial six figure dollar contract with the U.S. Navy for an Immersive Simulator, to be delivered in the first half of 2025.

Tyler Gates, General Manager of BLI and Glimpse’s Chief Futurist, stated, “Powered by BLI’s cutting-edge spatial computing platform (“SpatialCore”), we have created a game-changing technology that pushes the boundaries of what’s possible via the integration of AI and Spatial Computing. The Immersive Simulator system seamlessly integrates AI into both the full motion simulation and the spatial computing environments in which they operate, offering unparalleled realism, responsiveness, and adaptability, thereby opening up new possibilities for training, development, and operations across various industries in a cost-effective manner and much smaller form factor compared to existing advanced simulators.”

Lyron Bentovim, Glimpse’s President and CEO, added, “In partnership with the US Navy, we believe that the Immersive Simulator represents a key milestone in the world of advanced simulation technology, building on the momentum around Brightline’s vision for the SpatialCore platform.”

Painreform (NASDAQ: PRFX) is supposed to announce its financial results, in lieu of its typical 25th of the month reporting date.

Please go to 247marketnews.com to sign up for free MoBot alerts and view Mobot’s real time data.

24/7 Market News disclosure

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (SYTA, TPET, BPTH, PHIO, VRAR, PRFX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.